Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction - PubMed (original) (raw)
Clinical Trial
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989.
Abstract
The occurrence of ventricular premature depolarizations in survivors of myocardial infarction is a risk factor for subsequent sudden death, but whether antiarrhythmic therapy reduces the risk is not known. The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction. As of March 30, 1989, 2309 patients had been recruited for the initial drug-titration phase of the study: 1727 (75 percent) had initial suppression of their arrhythmia (as assessed by Holter recording) through the use of one of the three study drugs and had been randomly assigned to receive active drug or placebo. During an average of 10 months of follow-up, the patients treated with active drug had a higher rate of death from arrhythmia than the patients assigned to placebo. Encainide and flecainide accounted for the excess of deaths from arrhythmia and nonfatal cardiac arrests (33 of 730 patients taking encainide or flecainide [4.5 percent]; 9 of 725 taking placebo [1.2 percent]; relative risk, 3.6; 95 percent confidence interval, 1.7 to 8.5). They also accounted for the higher total mortality (56 of 730 [7.7 percent] and 22 of 725 [3.0 percent], respectively; relative risk, 2.5; 95 percent confidence interval, 1.6 to 4.5). Because of these results, the part of the trial involving encainide and flecainide has been discontinued. We conclude that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia. Whether these results apply to other patients who might be candidates for antiarrhythmic therapy is unknown.
Comment in
- The cardiac arrhythmia suppression trial (CAST).
Ruskin JN. Ruskin JN. N Engl J Med. 1989 Aug 10;321(6):386-8. doi: 10.1056/NEJM198908103210608. N Engl J Med. 1989. PMID: 2501683 No abstract available. - The cardiac arrhythmia suppression trial.
[No authors listed] [No authors listed] N Engl J Med. 1989 Dec 21;321(25):1754-6. doi: 10.1056/NEJM198912213212510. N Engl J Med. 1989. PMID: 2535645 No abstract available.
Similar articles
- Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Am J Cardiol. 1988 Mar 1;61(8):501-9. doi: 10.1016/0002-9149(88)90754-0. Am J Cardiol. 1988. PMID: 2894169 Clinical Trial. - Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Echt DS, et al. N Engl J Med. 1991 Mar 21;324(12):781-8. doi: 10.1056/NEJM199103213241201. N Engl J Med. 1991. PMID: 1900101 Clinical Trial. - Treatment of ventricular arrhythmias after CAST.
Tonkin AM. Tonkin AM. Med J Aust. 1992 Apr 6;156(7):488-92. doi: 10.5694/j.1326-5377.1992.tb126477.x. Med J Aust. 1992. PMID: 1372950 Review. - Encainide--an updated safety profile.
Thomis JA. Thomis JA. Cardiovasc Drugs Ther. 1990 Jun;4 Suppl 3:585-94. doi: 10.1007/BF00357035. Cardiovasc Drugs Ther. 1990. PMID: 2125837 Review.
Cited by
- Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic.
Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Yang T, et al. Circ Res. 2012 Jul 20;111(3):322-32. doi: 10.1161/CIRCRESAHA.112.265173. Epub 2012 Jun 20. Circ Res. 2012. PMID: 22723299 Free PMC article. - A model model: a commentary on DiFrancesco and Noble (1985) 'A model of cardiac electrical activity incorporating ionic pumps and concentration changes'.
Dibb K, Trafford A, Zhang H, Eisner D. Dibb K, et al. Philos Trans R Soc Lond B Biol Sci. 2015 Apr 19;370(1666):20140316. doi: 10.1098/rstb.2014.0316. Philos Trans R Soc Lond B Biol Sci. 2015. PMID: 25750236 Free PMC article. Review. - Hyperglycemia is associated with corrected QT prolongation and mortality in acutely ill patients.
Pickham D, Flowers E, Drew BJ. Pickham D, et al. J Cardiovasc Nurs. 2014 May-Jun;29(3):264-70. doi: 10.1097/JCN.0b013e31827f174c. J Cardiovasc Nurs. 2014. PMID: 23364575 Free PMC article. - Enhancing clinical evidence by proactively building quality into clinical trials.
Meeker-O'Connell A, Glessner C, Behm M, Mulinde J, Roach N, Sweeney F, Tenaerts P, Landray MJ. Meeker-O'Connell A, et al. Clin Trials. 2016 Aug;13(4):439-44. doi: 10.1177/1740774516643491. Epub 2016 Apr 20. Clin Trials. 2016. PMID: 27098014 Free PMC article. - Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.
Nattel S. Nattel S. Drugs. 1991 May;41(5):672-701. doi: 10.2165/00003495-199141050-00002. Drugs. 1991. PMID: 1712704 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous